"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 8 | 10 |
| 1996 | 2 | 16 | 18 |
| 1997 | 4 | 15 | 19 |
| 1998 | 7 | 11 | 18 |
| 1999 | 2 | 21 | 23 |
| 2000 | 7 | 18 | 25 |
| 2001 | 4 | 24 | 28 |
| 2002 | 7 | 39 | 46 |
| 2003 | 9 | 27 | 36 |
| 2004 | 6 | 17 | 23 |
| 2005 | 9 | 16 | 25 |
| 2006 | 6 | 19 | 25 |
| 2007 | 8 | 7 | 15 |
| 2008 | 3 | 15 | 18 |
| 2009 | 8 | 14 | 22 |
| 2010 | 8 | 8 | 16 |
| 2011 | 6 | 11 | 17 |
| 2012 | 3 | 12 | 15 |
| 2013 | 5 | 8 | 13 |
| 2014 | 7 | 5 | 12 |
| 2015 | 6 | 5 | 11 |
| 2016 | 5 | 4 | 9 |
| 2017 | 7 | 1 | 8 |
| 2018 | 9 | 4 | 13 |
| 2019 | 9 | 4 | 13 |
| 2020 | 5 | 4 | 9 |
| 2021 | 6 | 2 | 8 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
-
Development of an Acrylamide-Based Inhibitor of Protein S-Acylation. ACS Chem Biol. 2021 08 20; 16(8):1546-1556.
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
-
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia. Elife. 2021 07 15; 10.
-
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 09 10; 39(26):2881-2892.
-
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML. Br J Haematol. 2021 09; 194(6):1083-1085.
-
Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun Biol. 2021 02 09; 4(1):193.
-
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292.
-
Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun. 2021 01 05; 12(1):121.
-
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.